Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on IT Press Releases.
Press releases published on September 30, 2025
Scannx Expands Partnership with CCP Solutions to Distribute the ScannX Multi-Function Printer Designed for Libraries
PLEASANTON, CA, UNITED STATES, September 29, 2025 /EINPresswire.com/ -- ScannX Inc., a leading developer of cloud-based, self-service book and document scanning solutions, announced today that it appointed CCP Solutions, a leading provider of copier, …
Equipment Management Software Market to Expand at a 9.5% CAGR by 2029, Reaching US $15.06 Billion
The Business Research Company's Equipment Management Software Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, September 30, 2025 /EINPresswire.com/ -- "Get 30% Off All Global Market …
Sapu Nano 的 Sapu003 进入人体临床试验 —— 革新给药方式，实现 Everolimus 全生物利用度，造福乳腺癌患者
Sapu003 旨在克服 Afinitor®（FDA 批准的口服 Everolimus）的局限性，通过静脉注射实现 Everolimus 的全效给药 悉尼澳大利亚, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Deciparticle™ 的开发公司 Sapu Nano 今日宣布，已获澳大利亚人类研究伦理委员会（HREC）批准，启动 Sapu003 的一期人体临床试验患者招募。Sapu003 是一种用于乳腺癌治疗的注射型 Everolimus 制剂。 Sapu Nano 隶属于 …
Sapu Nano 展開編號為 Sapu003 的臨床試驗 —— 以完全生體可用率革新 Everolimus(依維莫司) 給藥方式，為乳癌治療開啟新篇章
Sapu003 旨在突破 FDA 核准口服藥物 Everolimus（Afinitor®，癌伏妥）的療效瓶頸，以 靜脈注射方式提供完整且高效率的 Everolimus 輸送。 澳洲雪梨, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Deciparticle™ 技術的研發公司 Sapu Nano 今日宣布，已獲得澳洲 Human Research Ethics Committee（人類研究倫理委員會， HREC） 的批准，將正式啟動名為Sapu003（Everolimus …